AB Science S.A. (ABSCF)
OTCMKTS · Delayed Price · Currency is USD
1.450
+0.180 (14.17%)
At close: Dec 22, 2025
AB Science Revenue
AB Science had revenue of 515.00K EUR in the half year ending June 30, 2025, with 14.96% growth. This brings the company's revenue in the last twelve months to 1.03M, down -5.08% year-over-year. In the year 2024, AB Science had annual revenue of 1.07M with 10.52% growth.
Revenue (ttm)
1.03M EUR
Revenue Growth
-5.08%
P/S Ratio
95.46
Revenue / Employee
28.53K EUR
Employees
36
Market Cap
115.13M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.07M | 102.00K | 10.52% |
| Dec 31, 2023 | 970.00K | 12.00K | 1.25% |
| Dec 31, 2022 | 958.00K | -649.00K | -40.39% |
| Dec 31, 2021 | 1.61M | 24.00K | 1.52% |
| Dec 31, 2020 | 1.58M | 12.00K | 0.76% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sofgen Pharma | 423.75M |
| Jushi Holdings | 260.43M |
| MariMed | 157.38M |
| Elite Pharmaceuticals | 122.89M |
| Earth Science Tech | 33.84M |
| Radnostix | 14.07M |
| Healthy Extracts | 3.59M |
| Growth Stalk Holdings | 583.34K |
AB Science News
- 3 days ago - AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors - GlobeNewsWire
- 22 days ago - AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041 - GlobeNewsWire
- 5 weeks ago - AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia - GlobeNewsWire
- 7 weeks ago - AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040 - GlobeNewsWire
- 2 months ago - AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share - GlobeNewsWire
- 2 months ago - AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers - GlobeNewsWire
- 2 months ago - AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function - GlobeNewsWire
- 4 months ago - AB Science announces the successful completion of a EUR 2.8 million private placement - GlobeNewsWire